If you use assistive technology (such as a screen reader) and need a
version of this document in a more accessible format, please email email@example.com.
Please tell us what format you need. It will help us if you say what assistive technology you use.
In response to changes in available intravenous (IV) immunoglobulin products in the NHS, PHE commissioned NIBSC to undertake additional testing of 7 other IV immunoglobulin products to determine if they have similar levels of tetanus antibody and may be used as an alternative to the previously tested products.
Full details will be issued in the revised ‘PHE guidelines for management of clinical tetanus and of tetanus-prone wounds’, in 2018.
These updated recommendations, regarding immunoglobulin use for treatment and prophylaxis, are to used as interim guidance in response to current stock shortages and the 2018 NHS England approved list of commissioned immunoglobulin products.